Skip to main content
. 2013 Jul 29;110(33):13522–13527. doi: 10.1073/pnas.1310067110

Fig. 2.

Fig. 2.

RARα-PLZF impairs the expression of CEBPα target genes without affecting CEBPα expression levels. (A) Decreased expression of C/EBPα target genes in RARα-PLZF expressing clones compared with control 32D cells. mRNA levels for the indicated C/EBPα target genes were determined by real-time PCR as in Fig 1D. (B) Decreased expression of C/EBPα target genes in RP7/huCSF3R expressing clones compared with control 32D cells, as determined by real-time PCR analysis. (C) Protein levels of RARα-PLZF and C/EBPα in 32D clones and of RARα and C/EBPα in t(15;17) APL patient samples. Total protein extracts from 32D clones stably transduced with a TAP-RARα-PLZF (RP-TAP) or from t(15;17) APL blasts were subjected to Western blot analysis (representative of two experiments). (D) Molecular levels of C/EBPα and RARα-PLZF in 32D clones and in APL patients. Western blot signals were compared with signals from tagged protein standards expressed in BOSC cells (HA-hC/EBPα, hJUN-HA, hJUN-TAP) with antibodies against HA, TAP, C/EBPα, and RARα. Shown are the number of C/EBPα molecules per cell calculated based on the number of cells corresponding to 30 μg of extracts per lane. The number of RARα-PLZF and RARα molecules per cell was calculated as above and expressed as molecular ratio of RARα-PLZF to C/EBPα levels in 32D clones and of RARα to C/EBPα in APL patients.